Insider Selling: Atreca (NASDAQ:BCEL) Insider Sells 600 Shares of Stock

Atreca (NASDAQ:BCEL) insider Tito Serafini sold 600 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $25.01, for a total value of $15,006.00. Following the completion of the sale, the insider now owns 3,655 shares in the company, valued at approximately $91,411.55. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Tito Serafini also recently made the following trade(s):

  • On Monday, June 22nd, Tito Serafini sold 496 shares of Atreca stock. The shares were sold at an average price of $20.05, for a total value of $9,944.80.
  • On Friday, June 19th, Tito Serafini sold 4,604 shares of Atreca stock. The shares were sold at an average price of $20.03, for a total value of $92,218.12.
  • On Thursday, June 11th, Tito Serafini sold 10,000 shares of Atreca stock. The shares were sold at an average price of $17.44, for a total value of $174,400.00.
  • On Tuesday, May 26th, Tito Serafini sold 200 shares of Atreca stock. The shares were sold at an average price of $20.00, for a total value of $4,000.00.
  • On Monday, May 11th, Tito Serafini sold 10,000 shares of Atreca stock. The shares were sold at an average price of $18.00, for a total value of $180,000.00.
  • On Thursday, April 16th, Tito Serafini sold 10,000 shares of Atreca stock. The shares were sold at an average price of $16.28, for a total value of $162,800.00.

Shares of BCEL opened at $21.28 on Wednesday. The company has a market capitalization of $584.37 million and a price-to-earnings ratio of -3.74. The stock has a 50 day moving average of $18.85 and a 200 day moving average of $17.65. Atreca has a 12 month low of $9.51 and a 12 month high of $29.35.

Atreca (NASDAQ:BCEL) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.73) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.73). Sell-side analysts anticipate that Atreca will post -3.07 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp increased its position in shares of Atreca by 142.2% during the first quarter. State Street Corp now owns 282,909 shares of the company’s stock valued at $4,682,000 after acquiring an additional 166,100 shares during the last quarter. Barclays PLC increased its position in shares of Atreca by 57.4% during the fourth quarter. Barclays PLC now owns 7,969 shares of the company’s stock valued at $124,000 after acquiring an additional 2,906 shares during the last quarter. BlackRock Inc. increased its position in shares of Atreca by 42.0% during the first quarter. BlackRock Inc. now owns 1,863,589 shares of the company’s stock valued at $30,841,000 after acquiring an additional 551,189 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Atreca by 149.8% during the first quarter. Bank of New York Mellon Corp now owns 48,191 shares of the company’s stock valued at $797,000 after purchasing an additional 28,897 shares during the period. Finally, US Bancorp DE bought a new position in Atreca during the first quarter valued at $46,000. 62.14% of the stock is owned by institutional investors.

A number of equities research analysts have commented on BCEL shares. Canaccord Genuity reiterated a “buy” rating and issued a $23.00 price target on shares of Atreca in a research report on Friday, March 13th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Atreca in a research report on Tuesday, June 16th. ValuEngine upgraded Atreca from a “hold” rating to a “buy” rating in a research report on Thursday, March 5th. BidaskClub raised Atreca from a “hold” rating to a “buy” rating in a research note on Thursday, June 25th. Finally, Robert W. Baird assumed coverage on Atreca in a research note on Wednesday, April 15th. They set an “outperform” rating and a $30.00 price target on the stock. Eleven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $25.70.

About Atreca

Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Recommended Story: Basic Economics creates winners and losers

Insider Buying and Selling by Quarter for Atreca (NASDAQ:BCEL)

Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.